Study Of The Relationship Between Apolipoprotein Aâ…¡ And Chemotherapy Of Ovarian Cancer

Ovarian cancer ,which seriously threats women's lives and health,is the comment malignancy tumor. In recent, ovarian cancer has remained the highest mortality of gynecologic malignancies, despite progress in cancer therapy, such as new drug, chemotherapy and operation. The 5-year survival rate of ovarian cancer is long remained 30%.Currently, none of the methods for diagnosis and monitoring therapeutic effect.Therefore, it is urgent to find sensitive, specific and convenient biomarkers. Our prophase work found there was correlation between the expression of Apoa II and ovarian cancer chemotherapy by SELDI-TOF-MS, but the concrete mechanism need further study. Our study discussed the relationship between Apoa II and ovarian cancer chemotherapy, then we observed expression of Apoa II as the change of cisplatin in vitro, expected to find out direct evidence that Apoa II had correlated with chemotherapy of ovarian cancer.The serum level of Apoa II in ovarian malignant and its clinicalsignificance Objective:To investigate the serum levels of Apoa II in ovarian malignant and explores its clinical significance in human ovarian malignant.Methods: Immunoturbidimetry assay was used to detect the serum levels of Apoa II in 120 women (31 normal women,31 patients with benign ovarian tumer and 58 patients with ovarian malignant). The relations between the serum level of Apoa II and the clinico- pathological changes,between the serum level of Apoa II and the cchemotherapy, the serum level of Apoa II and prognosis were analyzed statistically.Results: the prochemotherapy serum level of Apoa II was 170.00±50.445mg/L in malignant groups ,and there were significant difference compared with benign tumors and healthy women(P<0.05).The chemotherapy serum level of Apoa II was 198.53±32.251mg/L ,which was significant difference compared with prochemotherapy malignant group(P<0.05).The serum level of Apoa II was 174.44±43.128mg/L in relapse group,and there was a significant difference compared healthy women(P<0.05),but no significant associations was found between the serum level of Apoa II and histological typing, stages and prognosis of ovarian malignant.Conclution: The serum level of Apoa II has correlated with ovarian cancer chemotherapy, and it might be a new biomarker for evaluating chemotherapy effect.The mRNA expression of Apoa II in ovarian malignant and its clinicalsignificanceObjective:To investigate the mRNA expression of Apoa II in different ovarian tissue, and explore its clinical significance in human ovarian malignant.Methods: RT-PCR was used to detect the mRNA expression of Apoa II in 73 patients (18 patients with normal ovarian,16 patients with benign ovarian tumer and 39 patients with ovarian malignant). The relations between the expression and the clinico- pathological changes,between the expression and chemotherapy,between the expression and prognosis were analyzed statistically.Results: Apoa II mRNA levels showed significantly higher in the patients with ovarian malignant compared to the normal and benign tumer(P<0.05), and it was different between difference ages (P<0.05). On the other hand, no significant associations were found between Apoa II expression and histological typing, stages, chemotherapy and prognosis of ovarian malignant.Conclution:The cause of abnormal expression of Apoa II in ovarian malignant is that metabolize change by chemotherapy,but not its gene,or neoadjuvant chemotherapy doesn't make the change of ovarian malignant cell molecule levels.The protein expression of Apoa II in ovarian malignant and its clinicalsignificanceObjective:To investigate the protein expression of Apoa II gene in different ovarian tissue, and explore its clinical significance in human ovarian malignant.Methods: Immunohistochemistry was used to detect the expression of Apoa II protein in 84 patients (13 patients with normal ovarian, 18 patients with benign ovarian tumer and 53 patients with ovarian malignant). The relations between the expression and the clinico- pathological changes,between the expression and the chemotherapy,between the expression and prognosis were analyzed statistically.Results: Apoa II protein levels showed significantly higher in the patients withovarian malignant compared to the normal and benign tumer(P<0.05). On theother hand, no significant associations were found between Apoa II proteinexpression and histological typing,stages,chemotherapy and prognosis ofovarian malignant.Conclution: The cause of abnormal expression of Apoa II in ovarian malignantis that metabolize change by chemotherapy,but not its protein ,or neoadjuvantchemotherapy doesn't make the change of ovarian malignant cell moleculelevels.The expression of Apoa II in ovarian malignant cells and study ofcisplatin in vitroObjective:To investigate the relationship between Apoa II and ovarian malignant chemothrapy, and explore its possible mechanism.Methods: RT-PCR and immunocytochemistry were used to detect the expression of Apoa II in ovarian malignant cells as the change of cisplatin in vitro,and explore its possible mechanism.Results: Apoa II protein expression of ovarian malignant chemotherapy sensitive cells increased as raise of cisplatin in vitro,however, it didn't detect this relationship in Apoa II mRNA expression .In other hand, it also didn't detect the Apoa II mRNA express in chemoresistance ovarian cancer cells.Conclution:We acquired direct evidences that Apoa II had correlation with ovarian malignant .Confirmed the clinical observation that Apoa II played an important role in ovarian malignant and its chemotherapy.